
New oral peptide ICOTYDE shows sustained clearance in psoriasis patients over two years
Johnson & Johnson announced two-year Phase 3 data for ICOTYDE (icotrokinra), an oral peptide targeting IL-23 receptor, showing sustained skin clearance in patients with moderate-to-severe plaque psoriasis, especially in sensitive areas like scalp and...





